Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial

S. Mook; H. Bonnefoi; G. Pruneri; D. Larsimont; J. Jaskiewicz; M. D. Sabadell; G. MacGrogan; L. J. van't Veer; F. Cardoso; E. J. Rutgers

doi:10.1016/j.ejca.2009.01.004

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial

S. Mook
, H. Bonnefoi
, G. Pruneri
, D. Larsimont
, J. Jaskiewicz
, M. D. Sabadell
, G. MacGrogan
, L. J. van't Veer
, F. Cardoso
, E. J. Rutgers^*

^*Corresponding author for this work

Antoni van Leeuwenhoek Hospital
University of Geneva
University of Milan
Université libre de Bruxelles
Medical University of Gdańsk
Hospital Universitari Vall d'Hebron
Centre Georges-François Leclerc
Agendia

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose: The 70-gene prognosis-signature is a prognostic tool for early breast cancer analysis. In addition to scientific evidence, implementation of the signature in clinical trials and daily practice requires logistical feasibility. The aim of our study was to test logistics for gene expression profiling on fresh frozen tumour tissue in the preparation for the prospective, multinational Microarray In Node-negative Disease may Avoid ChemoTherapy (MINDACT) trial. Methods: Sixty-four patients were included in six European hospitals. Fresh frozen tumour samples were shipped on dry ice to Agendia B.V., where RNA was isolated and subsequently hybridised on the 70-gene prognosis-signature (MammaPrint™). Results: Tumour samples were obtained in 60 of 64 patients. Among the 60 samples, 11 contained insufficient tumour cells (<50%) and three contained insufficient RNA quality. All 46 samples eligible for genomic profiling were successfully hybridised, and the results were reported on average within 4-5 d. Conclusion: Gene expression profiling on fresh frozen tissue is feasible in daily clinical practice. © 2009 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	1201-1208
Journal	European Journal of Cancer
Volume	45
Issue number	7
DOIs	https://doi.org/10.1016/j.ejca.2009.01.004
Publication status	Published - May 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ejca.2009.01.004

Cite this

Mook, S., Bonnefoi, H., Pruneri, G., Larsimont, D., Jaskiewicz, J., Sabadell, M. D., MacGrogan, G., van't Veer, L. J., Cardoso, F., & Rutgers, E. J. (2009). Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. European Journal of Cancer, 45(7), 1201-1208. https://doi.org/10.1016/j.ejca.2009.01.004

@article{ff45810a47be494184fc2212b6218460,

title = "Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial",

abstract = "Purpose: The 70-gene prognosis-signature is a prognostic tool for early breast cancer analysis. In addition to scientific evidence, implementation of the signature in clinical trials and daily practice requires logistical feasibility. The aim of our study was to test logistics for gene expression profiling on fresh frozen tumour tissue in the preparation for the prospective, multinational Microarray In Node-negative Disease may Avoid ChemoTherapy (MINDACT) trial. Methods: Sixty-four patients were included in six European hospitals. Fresh frozen tumour samples were shipped on dry ice to Agendia B.V., where RNA was isolated and subsequently hybridised on the 70-gene prognosis-signature (MammaPrint{\texttrademark}). Results: Tumour samples were obtained in 60 of 64 patients. Among the 60 samples, 11 contained insufficient tumour cells (<50\%) and three contained insufficient RNA quality. All 46 samples eligible for genomic profiling were successfully hybridised, and the results were reported on average within 4-5 d. Conclusion: Gene expression profiling on fresh frozen tissue is feasible in daily clinical practice. {\textcopyright} 2009 Elsevier Ltd. All rights reserved.",

author = "S. Mook and H. Bonnefoi and G. Pruneri and D. Larsimont and J. Jaskiewicz and Sabadell, \{M. D.\} and G. MacGrogan and \{van't Veer\}, \{L. J.\} and F. Cardoso and Rutgers, \{E. J.\}",

year = "2009",

month = may,

doi = "10.1016/j.ejca.2009.01.004",

language = "English",

volume = "45",

pages = "1201--1208",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "7",

}

Mook, S, Bonnefoi, H, Pruneri, G, Larsimont, D, Jaskiewicz, J, Sabadell, MD, MacGrogan, G, van't Veer, LJ, Cardoso, F & Rutgers, EJ 2009, 'Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial', European Journal of Cancer, vol. 45, no. 7, pp. 1201-1208. https://doi.org/10.1016/j.ejca.2009.01.004

TY - JOUR

T1 - Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial

AU - Mook, S.

AU - Bonnefoi, H.

AU - Pruneri, G.

AU - Larsimont, D.

AU - Jaskiewicz, J.

AU - Sabadell, M. D.

AU - MacGrogan, G.

AU - van't Veer, L. J.

AU - Cardoso, F.

AU - Rutgers, E. J.

PY - 2009/5

Y1 - 2009/5

N2 - Purpose: The 70-gene prognosis-signature is a prognostic tool for early breast cancer analysis. In addition to scientific evidence, implementation of the signature in clinical trials and daily practice requires logistical feasibility. The aim of our study was to test logistics for gene expression profiling on fresh frozen tumour tissue in the preparation for the prospective, multinational Microarray In Node-negative Disease may Avoid ChemoTherapy (MINDACT) trial. Methods: Sixty-four patients were included in six European hospitals. Fresh frozen tumour samples were shipped on dry ice to Agendia B.V., where RNA was isolated and subsequently hybridised on the 70-gene prognosis-signature (MammaPrint™). Results: Tumour samples were obtained in 60 of 64 patients. Among the 60 samples, 11 contained insufficient tumour cells (<50%) and three contained insufficient RNA quality. All 46 samples eligible for genomic profiling were successfully hybridised, and the results were reported on average within 4-5 d. Conclusion: Gene expression profiling on fresh frozen tissue is feasible in daily clinical practice. © 2009 Elsevier Ltd. All rights reserved.

AB - Purpose: The 70-gene prognosis-signature is a prognostic tool for early breast cancer analysis. In addition to scientific evidence, implementation of the signature in clinical trials and daily practice requires logistical feasibility. The aim of our study was to test logistics for gene expression profiling on fresh frozen tumour tissue in the preparation for the prospective, multinational Microarray In Node-negative Disease may Avoid ChemoTherapy (MINDACT) trial. Methods: Sixty-four patients were included in six European hospitals. Fresh frozen tumour samples were shipped on dry ice to Agendia B.V., where RNA was isolated and subsequently hybridised on the 70-gene prognosis-signature (MammaPrint™). Results: Tumour samples were obtained in 60 of 64 patients. Among the 60 samples, 11 contained insufficient tumour cells (<50%) and three contained insufficient RNA quality. All 46 samples eligible for genomic profiling were successfully hybridised, and the results were reported on average within 4-5 d. Conclusion: Gene expression profiling on fresh frozen tissue is feasible in daily clinical practice. © 2009 Elsevier Ltd. All rights reserved.

UR - https://www.scopus.com/pages/publications/64049113346

UR - https://www.ncbi.nlm.nih.gov/pubmed/19232484

U2 - 10.1016/j.ejca.2009.01.004

DO - 10.1016/j.ejca.2009.01.004

M3 - Article

C2 - 19232484

SN - 0959-8049

VL - 45

SP - 1201

EP - 1208

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 7

ER -

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this